The traditional complications of diabetes mellitus are well known and continue to pose a
considerable burden on millions of people living with diabetes mellitus. However, advances …

Introduction Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver
disease, with type 2 diabetes mellitus (T2DM) as a major predictor. Insulin resistance and …

With the global epidemics of obesity and associated conditions, including type 2 diabetes,
metabolic dysfunction-associated fatty liver disease, chronic kidney disease, hypertension …

The prevalence of non-alcoholic fatty liver disease (NAFLD) has been increasing rapidly
and at the forefront of worldwide concern. Characterized by excessive fat accumulation in …

Background There is an increased burden of diabetes globally including in sub-Saharan
Africa. The literature shows that glycaemic control among type 2 diabetes patients is poor in …

Background To determine the impact of metabolic syndrome (MetS) and/or metabolic
dysfunction-associated fatty liver disease (MAFLD), which are pathophysiologically similar …

After four decades since the term nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty
liver disease (NAFLD), there is growing evidence to suggest that they are rapidly becoming …

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with
type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric …

Objectives This network meta-analysis aims to compare the efficacy and safety of new anti-
diabetic medications for the treatment of non-alcoholic fatty liver disease (NAFLD). Materials …

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease
globally and is estimated to affect approximately 25% of the world's population. Data about …